Integrated Care Approach for Rheumatoid Arthritis Patients

Association Between Pro-inflammatory Cytokines and Depressive Symptoms in Patients With Rheumatoid Arthritis: Evaluating the Impact of an Integrated Care Approach

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06791980

Enrollment

Registered

2025-01-24

Start date

2024-10-01

Completion date

2025-12-31

Last updated

2026-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis (RA)

Brief summary

The goal of this study is to learn about the long-term effects of integrated care approach in persons over the age of 20 who take part in integrated care approach to treat their rheumatoid arthritis (RA). The main question is to explore whether adding the integrated care approach into routine care can lower pro-inflammatory cytokines and depressive symptom in RA persons over age 20 when taken long-term to treat RA?

Interventions

OTHERETLA

To assess the long-term effects of integrated case management model involving traditional Chinese medicine (CM-TCM) model. The persons participating will be invited to enroll in this stage, and they will be assigned to receive either the usual care or a usual care plus integrated 3-month CM-TCM

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Intervention model description

To set up an exercise training plus laser acupuncture (ETLA) program and to assess its long-term effects towards changes of metabolic profiles, pro-inflammatory cytokines, and muscle functions among RA persons.

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

age of at least 20 years; willingness to participate in the survey; having the physician-diagnosed RA with the International Classification of Diseases, 9th Revision, Clinical Modification code of 714.0

Exclusion criteria

* having physician-based diagnosis of cognitive impairment and with the ability to express opinion

Design outcomes

Primary

Measure	Time frame	Description
cytokines	From enrollment to the end of treatment at 12 weeks"	Serum cytokine levels contained interleukin (IL)-6, IL-1, IL-17 and tumor necrosis factor (TNF)-alpha,

Secondary

Measure	Time frame	Description
depressive symptom	From enrollment to the end of treatment at 12 weeks"	It is measured by self-reported scale

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 10, 2026